Personalized Search
Displaying 81 - 100 of 995
Presenter: Mikkael SekeresProfessor of Medicine, Chief, Division of Hematology, Sylvester Comprehensive Cancer Center, University of Miami Miller School of MedicineMiami, FL, USA
Release Date: December 20, 2024
Congress: ASH 2024
Area: Hematology
Description:
Mikkael A. Sekeres…
Article last updated
.
Node ID (debugging only): 1535
Several years ago, I wrote an emotionally difficult article titled "Will I Reach My Goal?" It was about a book I was writing. The book describes my life and what it was like being hard of hearing in the 60s and 70s without any support in the schools. It covers my experiences within the deaf community and how difficult it was when I lost more hearing from
chemotherapy
chemotherapy:
(kee-…
Article last updated
.
Node ID (debugging only): 1534
Key Points
VEN plus HMA induces superior response rates in patients with R/R AML than conventional salvage therapy.
The VEN plus HMA combination allows for a safe and effective bridging to allo-HCT.
Abstract
The B-cell lymphoma 2 inhibitor
venetoclax
venetoclax:
Venetoclax is used to treat chronic lymphocytic leukemia or small lymphocytic leukemia in adults. Venetoclax is used alone or…
Article last updated
.
Node ID (debugging only): 1533
Recent advances in
acute myeloid leukemia
acute myeloid leukemia:
(uh-KYOOT my-uh-LOYD loo-KEE-mee-uh) A cancer of the blood cells. It happens when very young white blood cells (blasts) in the bone marrow fail to mature. The blast cells stay in the bone marrow and become to numerous. This slows production of red blood cells and platelets. Some cases of MDS become…
(AML) come from…
Article last updated
.
Node ID (debugging only): 1532
Ziftomenib plus standard cytarabine and
daunorubicin
daunorubicin:
Daunorubicin is in a class of medications called anthracyclines. It works by slowing or stopping the growth of cancer cells in your body. It is used in combination with other chemotherapy drugs to treat a certain type of acute myeloid leukemia (AML).
chemotherapy
chemotherapy:
(kee-moe-THER-uh-…
Article last updated
.
Node ID (debugging only): 1531
Two new studies led by researchers at Washington University School of Medicine in St. Louis have identified a possible way to block the progression of several forms of blood cancer using a drug already in
clinical trials
clinical trials:
Clinical research is at the heart of all medical advances, identifying new ways to prevent, detect or treat disease. If you have a bone marrow failure…
Article last updated
.
Node ID (debugging only): 1530
In this issue of Blood, Antypiuk et al, utilizing a murine model, demonstrate that
iron overload
iron overload:
A condition that occurs when too much iron accumulates in the body. Bone marrow failure disease patients who need regular red blood cell transfusions are at risk for iron overload. Organ damage can occur if iron overload is not treated.
(IOL), accumulated via a
mutation…
Article last updated
.
Node ID (debugging only): 1529
Myelodysplastic syndromes
Myelodysplastic syndromes:
(my-eh-lo-diss-PLASS-tik SIN-dromez) A group of disorders where the bone marrow does not work well, and the bone marrow cells fail to make enough healthy blood cells. Myelo refers to the bone marrow. Dysplastic means abnormal growth or development. People with MDS have low blood cell count for at…
/neoplasms (MDS) are a widely…
Article last updated
.
Node ID (debugging only): 1528
Axatilimab-csfr (Niktimvo), a CSF-1R–targeting agent that reduces the drivers of inflammation and
fibrosis
fibrosis:
(fie-BRO-suss) Scarring of tissue. Fibrosis of the bone marrow is an feature seen in some types of unclassified myeldysplastic syndrome (MDS).
, has been approved by the FDA in 9 mg and 22 mg vial sizes to treat adult and pediatric patients with
graft-versus-host…
Article last updated
.
Node ID (debugging only): 1527
Panelists discuss how long-term analysis of the ELEMENTS trial reveals significant improvements in
red blood cell
red blood cell:
The most numerous type of blood cell in healthy people. Red blood cells contain hemoglobin, a protein that picks up oxygen in the lungs and brings it to cells in all parts of the body. Also called erythrocyte, RBC.
(RBC) transfusion burden and
hemoglobin…
Article last updated
.
Node ID (debugging only): 1526
Watch these sessions 2024 Patient and Family Conference, held in partnership with the University of Chicago.
Aplastic Anemia
Advances in Treating PNH
Fatigue Management
Conference Event last updated
.
Node ID (debugging only): 870
In this issue of Blood, Pidala et al report on the results of a multicenter phase 2 trial, in which a
graft-versus-host disease (GVHD)
graft-versus-host disease (GVHD):
Also called GVHD, it is a common complication of bone marrow/stem cell transplantation. It is caused when the donor's immune cells, now in the patient, begin to see the the patient's body as…
Article last updated
.
Node ID (debugging only): 1525
TITLE
Azacitidine
Azacitidine:
It works by reducing the amount of methylation in the body. Methylation is a process that acts like a switch to turn off or “silence” genes in certain cells. When these genes (called tumor suppressor genes) are turned off, MDS cells and cancer cells can grow freely. Azacitidine is approved by the U…
and
venetoclax
venetoclax:
Venetoclax is…
Article last updated
.
Node ID (debugging only): 1524
Allogeneic hematopoietic cell transplantation (HCT) is a potentially curative treatment for severe
aplastic anemia
aplastic anemia:
(ay-PLASS-tik uh-NEE_mee-uh) A rare and serious condition in which the bone marrow fails to make enough blood cells - red blood cells, white blood cells, and platelets. The term aplastic is a Greek word meaning not to form. Anemia is a condition that…
Article last updated
.
Node ID (debugging only): 1523
It is being increasingly recognized that many patients with blood cancers harbor germline variants that increase cancer risk.1 For example, 14% of patients with
acute myeloid leukemia
acute myeloid leukemia:
(uh-KYOOT my-uh-LOYD loo-KEE-mee-uh) A cancer of the blood cells. It happens when very young white blood cells (blasts) in the bone marrow fail to mature. The blast cells stay in…
Article last updated
.
Node ID (debugging only): 1522
2024 Patient and Family Conference in Los Angeles
Session Recordings:
Transplant for Aplastic Anemia and MDS
Emerging Therapies in High-Risk MDS
Cardiovascular Concerns after HCT
Supportive Care Management
Advances in the Therapy of PNH
Advances in Treating Lower-Risk MDS
Palliative Care
Living with Chronic GVHD
A Patient Story
Inherited Bone Marrow Failure Syndromes
Advances in…
Conference Event last updated
.
Node ID (debugging only): 868
Key Points
A 3-parameter CCRS model was devised specifically for patients diagnosed with clonal
cytopenia
cytopenia:
(sie-tuh-PEE-nee-uh) A shortage of one or more blood cell types. Also called a low blood count.
.
The CCRS offers precise CCUS risk assessment for patient management and
clinical trial
clinical trial:
A type of research study that tests how a drug, medical…
Article last updated
.
Node ID (debugging only): 1521
Abstract
TP53 is a tumor suppressor gene frequently mutated in human cancers and is generally associated with poor outcomes. TP53 mutations are found in approximately 5% to 10% of patients with
de novo
de novo:
(di-NO-vo) Brand new, referring to the first time something occurs. MDS that is untreated or that has no known cause is called de novo MDS.
acute myeloid leukemia
acute…
Article last updated
.
Node ID (debugging only): 1520
Key Points
This study illustrates the survival benefits of abatacept combined with CNI/MTX in patients with hematologic malignancies undergoing HCT.
The addition of abatacept may provide an approach for alternative donor pool expansion when
HLA
HLA:
See human leukocyte antigen.
-identical sibling donors are unavailable.
Abstract
Abatacept plus calcineurin inhibitors/methotrexate (CNI/…
Article last updated
.
Node ID (debugging only): 1519
Abstract
The genomics era has facilitated the discovery of new genes that predispose individuals to
bone marrow failure
bone marrow failure:
A condition that occurs when the bone marrow stops making enough healthy blood cells. The most common of these rare diseases are aplastic anemia, myelodysplastic syndromes (MDS) and paroxysmal nocturnal hemoglobinuria (PNH). Bone marrow failure can…
Article last updated
.
Node ID (debugging only): 1518